| Literature DB >> 30343322 |
H Bezstarosti1, E M M Van Lieshout1, L W Voskamp1, K Kortram1, W Obremskey2, M A McNally3, W J Metsemakers4, M H J Verhofstad5.
Abstract
INTRODUCTION: Standardized guidelines for treatment of fracture-related infection (FRI) are lacking. Worldwide many treatment protocols are used with variable success rates. Awareness on the need of standardized, evidence-based guidelines has increased in recent years. This systematic literature review gives an overview of available diagnostic criteria, classifications, treatment protocols, and related outcome measurements for surgically treated FRI patients.Entities:
Keywords: Classification; Definition; Diagnosis; Fracture-related infection; Outcome measurements; Treatment
Mesh:
Substances:
Year: 2018 PMID: 30343322 PMCID: PMC6342870 DOI: 10.1007/s00402-018-3048-0
Source DB: PubMed Journal: Arch Orthop Trauma Surg ISSN: 0936-8051 Impact factor: 3.067
Fig. 1Flowchart of the study
Overview of locations of FRI
| Location of FRI | All studies, |
|---|---|
| Tibia | 2533 (68.3%) |
| Femur | 599 (16.1%) |
| Ankle | 124 (3.3%) |
| Calcaneus | 77 (2.1%) |
| Foot | 63 (1.7%) |
| Humerus | 59 (1.6%) |
| Knee | 49 (1.3%) |
| Fibula | 30 (0.8%) |
| Radius | 24 (0.6%) |
| Forearm | 24 (0.6%) |
| Ulna | 18 (0.5%) |
| Ilium | 13 (0.4%) |
| Elbow | 11 (0.3%) |
| Clavicle | 4 (0.1%) |
| Spine | 1 (0.0%) |
| Skull | 1 (0.0%) |
| Not specified | 197 (5.3%) |
| Lower extremity not defined | 41 (1.1%) |
| Upper extremity not defined | 21 (0.6%) |
Overview of parameters used to diagnose or define FRI
| Parameters associated with FRI | Number of studies, |
|---|---|
| Clinical signs | |
| Purulent drainage (or discharge) | 34 (37%) |
| Dolor (pain) | 14 (15%) |
| Tumor (swelling) | 9 (10%) |
| Calor (warmth) | 8 (9%) |
| Rubor (redness) | 7 (8%) |
| Wound dehiscence/breakdown | 7 (8%) |
| Fever | 5 (5%) |
| Unspecified | 46 (49%) |
| Laboratory testing | |
| C-reactive protein (CRP) | 17 (18%) |
| Unspecified | 9 (10%) |
| Radiological signs | |
| Signs of osteomyelitis | 62 (67%) |
| Evidence of non-union | 34 (37%) |
| Bacteriological/histological findings | |
| Cultures taken | 56 (60%) |
| Unspecified histology | 17 (18%) |
| Unspecified bacteriology | 15 (16%) |
| Other | |
| Time of infection | 27 (29%) |
| No parameters for diagnosis given | 8 (9%) |
Classifications used to define FRI
| Classification System | Number of studies, |
|---|---|
| Cierny-Mader classification | 34 (72%) |
| May’s classification | 4 (9%) |
| Jain and Sinha’s modified May classification | 2 (4%) |
| Calori’s classification for non-union | 1 (2%) |
| CDC guidelines for wound infection | 1 (2%) |
| Osteomyelitis diagnosis score | 1 (2%) |
| UTMB staging system for adult osteomyelitis | 1 (2%) |
| Weiland classification | 1 (2%) |
| Yang’s classification for bone defects | 1 (2%) |
| Ziran’s algorithm for acute infection after ORIF | 1 (2%) |
Periods defined in classification of FRI
| Time frame | Number of studies |
|---|---|
| Chronic infection | 12 (13%) |
| > 6 weeks | 3 (3%) |
| > 12 weeks | 3 (3%) |
| > 4 months | 2 (2%) |
| > 6 months | 4 (4%) |
| Infected non-union | 12 (13%) |
| > 3 months | 1 (1%) |
| > 4 months | 1 (1%) |
| > 6 months | 9 (10%) |
| > 12 months | 1 (1%) |
| Multiple divisions | 3 (3%) |
| Acute < 2 weeks, Subacute 2–6 weeks, Chronic > 6 weeks | 1 (1%) |
| Acute < 30 days, Subacute 1–6 months, Chronic > 6 months | 2 (2%) |
| No period of time mentioned | 66 (71%) |
Surgical Protocol and Type of Fixation
| Number of stages | Number of studies, |
|---|---|
| One-stage | 18 (19%) |
| Two-stage | 50 (54%) |
| Three-stage | 7 (8%) |
| Combination of the above | 10 (11%) |
| Unknown | 16 (17%) |
Multidisciplinary approach in treatment of FRI
| Specialists involved | Number of studies, |
|---|---|
| Trauma/orthopedic surgeon | 10 (83%) |
| Infectious disease specialist | 5 (42%) |
| Plastic surgeon | 5 (42%) |
| Pharmacist | 1 (8%) |
| Radiologist | 1 (8%) |
| Team not defined | 3 (25%) |
Bone grafts used in treatment of FRI
| Graft type used (62 studies) | |
|---|---|
| Cancellous bone | 555 (39) |
| Iliac crest | 445 (31) |
| RIA (with BMP-7) | 76 (5) |
| Tibia condyle | 25 (2) |
| Femur condyle | 9 (1) |
| Vascularized bone | 381 (27) |
| Vascularized fibula | 322 (23) |
| Latissimus dorsi with rib | 41 (3) |
| Vascularized ilium | 18 (1) |
| Other | 27 (2) |
| Graft not defined | 455 (32) |
Muscle and skin flaps used in treatment of FRI
| Total (41 studies) | |
|---|---|
| Free flap | 460 (39) |
| Latissimus dorsi | 206 (18) |
| Not defined | 82 (7) |
| Gracilis | 64 (5) |
| Rectus abdominis | 47 (4) |
| Scapular skin flap | 23 (2) |
| Serratus anterior | 23 (2) |
| Lateral thigh | 15 (1) |
| Rotational flap | 125 (11) |
| Gastrocnemius | 52 (4) |
| Saphenous | 50 (4) |
| Soleus | 23 (2) |
| Skin | 247 (21) |
| Split skin graft | 232 (20) |
| Full thickness skin graft | 15 (1) |
| Other | 76 (1) |
| Skin/muscle not defined | 200 (17) |
Parameters used during follow-up of FRI
| Parameter | Number of studies, |
|---|---|
| Predefined routine follow-up episodes | 26 (28%) |
| Clinical signs of infection | 31 (33%) |
| Routine radiological check up | 49 (53%) |
| Blood biomarkers | 32 (34%) |
| C-reactive protein | 12 (13%) |
| Erythrocyte sedimentation rate | 10 (11%) |
| Leucocyte count | 4 (4%) |
| Complete blood count | 2 (2%) |
| Undefined | 4 (4%) |
| Bone scoring systems | 5 (5%) |
| ASAMI | 4 (4%) |
| Bahr score | 1 (1%) |
| Functional outcome scoring systems | 19 (20%) |
| Self-defined functionality scores | 5 (5%) |
| Paley’s functionality score | 3 (3%) |
| American orthopaedic foot and ankle society score | 1 (1%) |
| EuroQol 5D | 1 (1%) |
| Johner-Wruhs evaluation criteria | 1 (1%) |
| Lower extremity functionality scale | 1 (1%) |
| Ma’s knee score | 1 (1%) |
| Mazur’s ankle evaluation grading system | 1 (1%) |
| Merchant and Dietz score | 1 (1%) |
| SF-12 | 1 (1%) |
| SF-36 | 1 (1%) |
| Shahcheraghi and Bayatpoor evaluation score | 1 (1%) |
| Stewart and Hundley criteria | 1 (1%) |
Outcomes of FRI treatment
| Proportional variable | Studies ( | FRI ( | Chi2 ( | Pooled proportion (95% CI) | |
|---|---|---|---|---|---|
| Primary healing | 93 | 3711 | * | 81% (77–84) | 85% (82–88) |
| Total healing | 92 | 3695 | * | 77% (72–81) | 93% (91–94) |
| Infection recurrence | 89 | 3598 | * | 73% (66–78) | 9% (7–11) |
| Amputation rate | 83 | 3226 | * | 50% (35–61) | 3% (3–5) |
*p < 0.0001
aPer patient
bSince most of the individual studies did not report a standard deviation (SD) or standard error, no pooled SD could be provided